Literature DB >> 2439799

Double-blind comparison of the beta 1-selectivity of single doses of bisoprolol and atenolol.

P C Chang, S van Veen, P Vermeij, P van Brummelen.   

Abstract

The beta 1-adrenoceptor selectivity of bisoprolol (BPL) was investigated using the forearm circulation of eight healthy subjects. Each subject was studied twice, with at least 10 days in between each investigation. A brachial artery was cannulated for intra-arterial (i.a.) monitoring of blood pressure and for i.a. infusion of isoproterenol (ISO) and epinephrine (EPI). ISO was given in doses of 0.02-0.10-0.40 and 1.20 ng/kg/min, for 3 min per dose. After 20 min rest, EPI was infused in doses of 0.08 and 2.0 ng/kg/min for 6 min per dose. Subsequently, the subjects received an oral dose of either 20 mg BPL or 100 mg atenolol (ATL), and 2 h later, the ISO and EPI infusions were repeated. Forearm blood flow was measured by venous occlusion strain-gauge plethysmography. ISO produced a dose-dependent vasodilatation, whereas the response to EPI varied between individuals. After administration of BPL and ATL, the ISO dose-response curves were shifted to the right by 2.8 and 2.6 times, respectively (both p less than 0.01). Both beta-blockers influenced the vascular effect of EPI in the direction of vasoconstriction. However, this was only significant for ATL (p less than 0.05). From the latter observation it is concluded that BPL is slightly more beta 1-adrenoceptor-selective than ATL, using the forearm vascular bed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2439799     DOI: 10.1097/00005344-198511001-00009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension.

Authors:  M S Dixon; P Thomas; D J Sheridan
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers.

Authors:  C Le Jeunne; J M Poirier; G Cheymol; O Ertzbischoff; F Engel; F C Hugues
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.